CN102227429B - 作为趋化因子受体调节剂的3-氨基环戊烷羧酰胺 - Google Patents
作为趋化因子受体调节剂的3-氨基环戊烷羧酰胺 Download PDFInfo
- Publication number
- CN102227429B CN102227429B CN200980147183.7A CN200980147183A CN102227429B CN 102227429 B CN102227429 B CN 102227429B CN 200980147183 A CN200980147183 A CN 200980147183A CN 102227429 B CN102227429 B CN 102227429B
- Authority
- CN
- China
- Prior art keywords
- trifluoromethyl
- amino
- carbonyl
- diazabicyclo
- anhydro
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
- 0 CCC*(C(CC1)CC1(C(*(CC1*(C2)C(C)=**)C2C1=C)=O)*(C)=C)C(C(C)(C)C(*)(C(C)C)*=C1*(C)CC)C1(*1CC1)O* Chemical compound CCC*(C(CC1)CC1(C(*(CC1*(C2)C(C)=**)C2C1=C)=O)*(C)=C)C(C(C)(C)C(*)(C(C)C)*=C1*(C)CC)C1(*1CC1)O* 0.000 description 4
- MCOPMLXHPNYMPU-XJJIGLNASA-N CC(C)(C)OC(N(C[C@@H]1C2)[C@@H]2CN1C([C@@](CC1)(C[C@@H]1N([C@@H](CCOC1)[C@@H]1OC)C(C(F)(F)F)=O)C(C)(C)O)=O)=O Chemical compound CC(C)(C)OC(N(C[C@@H]1C2)[C@@H]2CN1C([C@@](CC1)(C[C@@H]1N([C@@H](CCOC1)[C@@H]1OC)C(C(F)(F)F)=O)C(C)(C)O)=O)=O MCOPMLXHPNYMPU-XJJIGLNASA-N 0.000 description 1
- NJORUBSEKQXPEW-WUZPWTHYSA-N CC(C)(C)OC(N(C[C@@H]1C2)[C@@H]2CN1C([C@@](CC1)(C[C@@H]1N([C@@H](CCOC1)[C@@H]1OC)C(C(F)(F)F)=O)C1(CCC1)OC(C)=O)=O)=O Chemical compound CC(C)(C)OC(N(C[C@@H]1C2)[C@@H]2CN1C([C@@](CC1)(C[C@@H]1N([C@@H](CCOC1)[C@@H]1OC)C(C(F)(F)F)=O)C1(CCC1)OC(C)=O)=O)=O NJORUBSEKQXPEW-WUZPWTHYSA-N 0.000 description 1
- OAKHTXKDPQXCIC-KKPNGEORSA-N CC(C)(C)OC(N(C[C@H]1N(C2)c3nccc(C(F)(F)F)c3)[C@H]2C1O)=O Chemical compound CC(C)(C)OC(N(C[C@H]1N(C2)c3nccc(C(F)(F)F)c3)[C@H]2C1O)=O OAKHTXKDPQXCIC-KKPNGEORSA-N 0.000 description 1
- BETGJOXYTQTEPO-GCJDJSOWSA-N CC(C)(C)OC(N(C[C@H]1NC2)[C@H]2C1O)=O Chemical compound CC(C)(C)OC(N(C[C@H]1NC2)[C@H]2C1O)=O BETGJOXYTQTEPO-GCJDJSOWSA-N 0.000 description 1
- RJNNXWKWUCMJGB-MQMGHXAXSA-N CC(C)([C@](CC1)(C[C@@H]1N[C@@H](CCOC1)[C@@H]1OC)C(N(C[C@@H]1C2)[C@@H]2CN1c1cc(C(F)(F)F)ncc1)=O)O Chemical compound CC(C)([C@](CC1)(C[C@@H]1N[C@@H](CCOC1)[C@@H]1OC)C(N(C[C@@H]1C2)[C@@H]2CN1c1cc(C(F)(F)F)ncc1)=O)O RJNNXWKWUCMJGB-MQMGHXAXSA-N 0.000 description 1
- OCPSWFCXLVUTKQ-YYNBNFOPSA-N CC(C)[C@@](C1)(C=C[C@H]1/C=N/[C@@H](CCOC1)[C@@H]1OC)C(N(C[C@@H]1C2)[C@@H]2CN1c1cccc(C(F)(F)F)n1)=O Chemical compound CC(C)[C@@](C1)(C=C[C@H]1/C=N/[C@@H](CCOC1)[C@@H]1OC)C(N(C[C@@H]1C2)[C@@H]2CN1c1cccc(C(F)(F)F)n1)=O OCPSWFCXLVUTKQ-YYNBNFOPSA-N 0.000 description 1
- AYGHWHNGAHYUKL-YFJVBQAUSA-N CC(C)[C@](CC1)(C[C@@H]1/C=N/[C@@H](CCOC1)[C@@H]1OC)C(N(C[C@@H]1C2)[C@@H]2CN1c1cc(C(F)(F)F)nc(C(F)(F)F)c1)=O Chemical compound CC(C)[C@](CC1)(C[C@@H]1/C=N/[C@@H](CCOC1)[C@@H]1OC)C(N(C[C@@H]1C2)[C@@H]2CN1c1cc(C(F)(F)F)nc(C(F)(F)F)c1)=O AYGHWHNGAHYUKL-YFJVBQAUSA-N 0.000 description 1
- YRRHRDDUJDWJNS-GKNGNAOLSA-N CO[C@H](COCC1)[C@H]1N[C@H](CC1)C[C@@]1(C(C(F)(F)F)O)C(N(C[C@@H]1C2)[C@@H]2CN1c1ccnc(C(F)(F)F)n1)=O Chemical compound CO[C@H](COCC1)[C@H]1N[C@H](CC1)C[C@@]1(C(C(F)(F)F)O)C(N(C[C@@H]1C2)[C@@H]2CN1c1ccnc(C(F)(F)F)n1)=O YRRHRDDUJDWJNS-GKNGNAOLSA-N 0.000 description 1
- QDOADAPYFMASTQ-VHFSTGMOSA-N CO[C@H](COCC1)[C@H]1N[C@H](CC1)C[C@H]1C(N(C[C@@H]1C2)[C@@H]2CN1c1nccc(C(F)(F)F)c1)=O Chemical compound CO[C@H](COCC1)[C@H]1N[C@H](CC1)C[C@H]1C(N(C[C@@H]1C2)[C@@H]2CN1c1nccc(C(F)(F)F)c1)=O QDOADAPYFMASTQ-VHFSTGMOSA-N 0.000 description 1
- NLITZQDXQNVFEB-RGKOJQFUSA-N CO[C@H]1[C@@H](CCC[C@H](CC2)C[C@@]2(CC(F)F)C(N(C[C@@H]2C3)[C@@H]3CN2c2nc(C(F)(F)F)ccc2)=O)CCOC1 Chemical compound CO[C@H]1[C@@H](CCC[C@H](CC2)C[C@@]2(CC(F)F)C(N(C[C@@H]2C3)[C@@H]3CN2c2nc(C(F)(F)F)ccc2)=O)CCOC1 NLITZQDXQNVFEB-RGKOJQFUSA-N 0.000 description 1
- SSTIDYXGQYDDDZ-ZBIJSRSNSA-N CO[C@H]1[C@@H](CCC[C@H](CC2)C[C@@]2(CC(F)F)C(N(C[C@@H]2C3)[C@@H]3CN2c2nc(C(F)(F)F)ncc2)=O)CCOC1 Chemical compound CO[C@H]1[C@@H](CCC[C@H](CC2)C[C@@]2(CC(F)F)C(N(C[C@@H]2C3)[C@@H]3CN2c2nc(C(F)(F)F)ncc2)=O)CCOC1 SSTIDYXGQYDDDZ-ZBIJSRSNSA-N 0.000 description 1
- KZWTVSPHZPRNRJ-SKZKBGNNSA-N C[C@H](COCC1)[C@H]1N[C@H](CC1)C[C@@]1(C(C)(C)O)C(N(C[C@@H]1C2)[C@@H]2CN1c1ccnc(C(F)(F)F)n1)=O Chemical compound C[C@H](COCC1)[C@H]1N[C@H](CC1)C[C@@]1(C(C)(C)O)C(N(C[C@@H]1C2)[C@@H]2CN1c1ccnc(C(F)(F)F)n1)=O KZWTVSPHZPRNRJ-SKZKBGNNSA-N 0.000 description 1
- IFDGSTIIEXETJZ-SZBHIRRCSA-N OC([C@@H](C1)NC2)[C@@H]2N1c1nccc(C(F)(F)F)c1 Chemical compound OC([C@@H](C1)NC2)[C@@H]2N1c1nccc(C(F)(F)F)c1 IFDGSTIIEXETJZ-SZBHIRRCSA-N 0.000 description 1
- HGYIBUDJAODOHS-XFKKCKKNSA-N OC1[C@@H]2N(Cc3ccccc3)C[C@H]1NC2 Chemical compound OC1[C@@H]2N(Cc3ccccc3)C[C@H]1NC2 HGYIBUDJAODOHS-XFKKCKKNSA-N 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/08—Bridged systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/407—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with other heterocyclic ring systems, e.g. ketorolac, physostigmine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/02—Nasal agents, e.g. decongestants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/04—Antipruritics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/04—Drugs for skeletal disorders for non-specific disorders of the connective tissue
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/06—Antigout agents, e.g. antihyperuricemic or uricosuric agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/16—Otologicals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A61P29/02—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID] without antiinflammatory effect
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/02—Nutrients, e.g. vitamins, minerals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biomedical Technology (AREA)
- Immunology (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Diabetes (AREA)
- Pulmonology (AREA)
- Dermatology (AREA)
- Rheumatology (AREA)
- Pain & Pain Management (AREA)
- Physical Education & Sports Medicine (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Heart & Thoracic Surgery (AREA)
- Communicable Diseases (AREA)
- Endocrinology (AREA)
- Urology & Nephrology (AREA)
- Oncology (AREA)
- Cardiology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Reproductive Health (AREA)
- Emergency Medicine (AREA)
- Ophthalmology & Optometry (AREA)
- Hospice & Palliative Care (AREA)
- Psychiatry (AREA)
- Nutrition Science (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US11805308P | 2008-11-26 | 2008-11-26 | |
| US61/118,053 | 2008-11-26 | ||
| PCT/IB2009/055232 WO2010061329A1 (en) | 2008-11-26 | 2009-11-20 | 3-aminocyclopentanecarboxamides as chemokine receptor modulators |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN102227429A CN102227429A (zh) | 2011-10-26 |
| CN102227429B true CN102227429B (zh) | 2014-05-28 |
Family
ID=41693100
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN200980147183.7A Expired - Fee Related CN102227429B (zh) | 2008-11-26 | 2009-11-20 | 作为趋化因子受体调节剂的3-氨基环戊烷羧酰胺 |
Country Status (38)
Families Citing this family (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| PL2370442T3 (pl) * | 2008-11-26 | 2013-08-30 | Pfizer | 3-Aminocyklopentanokarboksamidy jako modulatory receptora chemokiny |
| KR101303963B1 (ko) * | 2011-04-08 | 2013-09-05 | 재단법인 경기과학기술진흥원 | (1ｒ,2ｒ,3ｒ)-3-아미노사이클로펜탄-1,2-디올을 포함하는 항알러지용 조성물 |
| KR102359214B1 (ko) | 2014-04-04 | 2022-02-07 | 델 마 파마슈티컬스 | 폐의 비소세포 암종 및 난소암을 치료하기 위한 디안하이드로갈락티톨 및 이의 유사체 또는 유도체 |
| JP2016029038A (ja) * | 2014-07-17 | 2016-03-03 | 参天製薬株式会社 | 加齢黄斑変性の予防または治療剤 |
| PE20190972A1 (es) * | 2016-09-14 | 2019-07-09 | Novartis Ag | Combinacion de agonistas de fxr |
| TWI830733B (zh) * | 2018-05-11 | 2024-02-01 | 中國大陸商迪哲（江蘇）醫藥有限公司 | 環戊烷化合物 |
Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6812234B2 (en) * | 2002-04-29 | 2004-11-02 | Merck & Co., Inc. | Tetrahydropyranyl cyclopentyl tetrahydropyridopyridine modulators of chemokine receptor activity |
| CN1950082A (zh) * | 2004-03-03 | 2007-04-18 | 凯莫森特里克斯股份有限公司 | 双环和桥连的含氮杂环化物 |
| CN1976702A (zh) * | 2004-06-28 | 2007-06-06 | 因赛特公司 | 作为趋化因子受体调节剂的3－氨基环戊烷甲酰胺类 |
Family Cites Families (25)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU693143B2 (en) | 1993-12-06 | 1998-06-25 | Cytel Corporation | CS-1 peptidomimetics, compositions and methods of using the same |
| US5510332A (en) | 1994-07-07 | 1996-04-23 | Texas Biotechnology Corporation | Process to inhibit binding of the integrin α4 62 1 to VCAM-1 or fibronectin and linear peptides therefor |
| EP0769958B1 (en) | 1994-07-11 | 2003-04-16 | Athena Neurosciences, Inc. | Inhibitors of leukocyte adhesion |
| US5462208A (en) | 1994-08-01 | 1995-10-31 | The Procter & Gamble Company | Two-phase dispensing systems utilizing bellows pumps |
| US5811391A (en) | 1994-08-25 | 1998-09-22 | Cytel Corporation | Cyclic CS-1 peptidomimetics, compositions and methods of using same |
| GB9524630D0 (en) | 1994-12-24 | 1996-01-31 | Zeneca Ltd | Chemical compounds |
| US6306840B1 (en) | 1995-01-23 | 2001-10-23 | Biogen, Inc. | Cell adhesion inhibitors |
| AU5259296A (en) | 1995-04-07 | 1996-10-23 | Warner-Lambert Company | Flavones and coumarins as agents for the treatment of athero sclerosis |
| US5704960A (en) | 1995-12-20 | 1998-01-06 | Corning, Inc. | Method of forming an optical fiber for reduced polarization effects in amplifiers |
| GB9603741D0 (en) | 1996-02-22 | 1996-04-24 | Lin Mei | Treatment of water by electrolysis |
| JP2000516210A (ja) | 1996-07-12 | 2000-12-05 | ロイコサイト，インコーポレーテッド | ケモカインレセプターアンタゴニストとその使用方法 |
| WO1998042656A1 (en) | 1997-03-21 | 1998-10-01 | Cytel Corporation | Novel compounds |
| EP1001764A4 (en) | 1997-05-29 | 2005-08-24 | Merck & Co Inc | HETEROCYCLIC AMIDE COMPOUNDS AS INHIBITORS OF CELL ADHESION |
| ATE318841T1 (de) | 1997-05-29 | 2006-03-15 | Merck & Co Inc | Biarylalkansäuren in der verwendung als zelladhäsionsinhibitoren |
| CA2291708A1 (en) | 1997-05-29 | 1998-12-03 | Merck & Co., Inc. | Sulfonamides as cell adhesion inhibitors |
| WO1998054207A1 (en) | 1997-05-30 | 1998-12-03 | Celltech Therapeutics Limited | Anti-inflammatory tyrosine derivatives |
| ATE249421T1 (de) | 1997-06-23 | 2003-09-15 | Tanabe Seiyaku Co | Inhibitoren der alpha4-beta1 vermittelten zelladhäsion |
| US6312689B1 (en) | 1998-07-23 | 2001-11-06 | Millennium Pharmaceuticals, Inc. | Anti-CCR2 antibodies and methods of use therefor |
| MY129850A (en) | 2002-04-29 | 2007-05-31 | Merck Sharp & Dohme | Tetrahydropyranyl cyclopentyl tetrahydropyridopyridine modulators of chemokine receptor activity |
| CA2550596C (en) | 2003-12-18 | 2011-03-15 | Incyte Corporation | 3-cycloalkylaminopyrrolidine derivatives as modulators of chemokine receptors |
| WO2005105092A2 (en) | 2004-04-28 | 2005-11-10 | Merck & Co., Inc. | 3,3-disubstituted tetrahydropyranyl cyclopentyl amide modulators of chemokine receptor activity |
| AU2005259983B2 (en) * | 2004-06-28 | 2011-07-28 | Incyte Corporation | 3-aminocyclopentanecarboxamides as modulators of chemokine receptors |
| AP2006003849A0 (en) | 2004-06-28 | 2006-12-31 | Incyte Corp | 3-Aminocyclopentanecarboxamides as modulators of chemokine receptors |
| MEP1008A (xx) | 2005-12-21 | 2010-02-10 | Incyte Corp | 3-aminociklopentankarboksamidi kao modulatori receptora hemokina |
| PL2370442T3 (pl) * | 2008-11-26 | 2013-08-30 | Pfizer | 3-Aminocyklopentanokarboksamidy jako modulatory receptora chemokiny |
-
2009
- 2009-11-20 PL PL09774939T patent/PL2370442T3/pl unknown
- 2009-11-20 UA UAA201106571A patent/UA99978C2/uk unknown
- 2009-11-20 WO PCT/IB2009/055232 patent/WO2010061329A1/en not_active Ceased
- 2009-11-20 ME MEP-2011-83A patent/ME01144B/me unknown
- 2009-11-20 ES ES09774939T patent/ES2415430T3/es active Active
- 2009-11-20 CA CA2743030A patent/CA2743030C/en not_active Expired - Fee Related
- 2009-11-20 RS RS20130260A patent/RS52810B8/sr unknown
- 2009-11-20 PT PT97749394T patent/PT2370442E/pt unknown
- 2009-11-20 JP JP2011538083A patent/JP5108153B2/ja not_active Expired - Fee Related
- 2009-11-20 HR HRP20130409AT patent/HRP20130409T2/hr unknown
- 2009-11-20 CN CN200980147183.7A patent/CN102227429B/zh not_active Expired - Fee Related
- 2009-11-20 AU AU2009321221A patent/AU2009321221B2/en not_active Ceased
- 2009-11-20 BR BRPI0920936-0A patent/BRPI0920936A2/pt not_active Application Discontinuation
- 2009-11-20 MX MX2011005526A patent/MX2011005526A/es active IP Right Grant
- 2009-11-20 SI SI200930601T patent/SI2370442T1/sl unknown
- 2009-11-20 MY MYPI20112377 patent/MY152557A/en unknown
- 2009-11-20 EP EP09774939.4A patent/EP2370442B9/en active Active
- 2009-11-20 PE PE2011001105A patent/PE20110831A1/es active IP Right Grant
- 2009-11-20 NZ NZ592919A patent/NZ592919A/xx not_active IP Right Cessation
- 2009-11-20 DK DK09774939.4T patent/DK2370442T5/da active
- 2009-11-20 AP AP2011005732A patent/AP3113A/xx active
- 2009-11-20 KR KR1020117011887A patent/KR101374412B1/ko not_active Expired - Fee Related
- 2009-11-20 GE GEAP200912239A patent/GEP20146064B/en unknown
- 2009-11-20 EA EA201170721A patent/EA020470B1/ru not_active IP Right Cessation
-
2010
- 2010-06-07 US US12/795,266 patent/US8293903B2/en active Active
-
2011
- 2011-05-05 IL IL212732A patent/IL212732A/en active IP Right Grant
- 2011-05-18 TN TN2011000254A patent/TN2011000254A1/fr unknown
- 2011-05-24 NI NI201100102A patent/NI201100102A/es unknown
- 2011-05-24 CO CO11064157A patent/CO6361921A2/es active IP Right Grant
- 2011-05-25 EC EC2011011081A patent/ECSP11011081A/es unknown
- 2011-05-25 DO DO2011000154A patent/DOP2011000154A/es unknown
- 2011-05-25 CL CL2011001223A patent/CL2011001223A1/es unknown
- 2011-05-26 SV SV2011003923A patent/SV2011003923A/es unknown
- 2011-05-26 CU CU2011000121A patent/CU24022B1/es active IP Right Grant
- 2011-05-26 CR CR20110275A patent/CR20110275A/es unknown
- 2011-05-26 MA MA33895A patent/MA32834B1/fr unknown
- 2011-06-01 ZA ZA2011/04069A patent/ZA201104069B/en unknown
-
2012
- 2012-09-14 US US13/616,375 patent/US8946413B2/en active Active
-
2013
- 2013-05-29 CY CY20131100427T patent/CY1114020T1/el unknown
Patent Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6812234B2 (en) * | 2002-04-29 | 2004-11-02 | Merck & Co., Inc. | Tetrahydropyranyl cyclopentyl tetrahydropyridopyridine modulators of chemokine receptor activity |
| CN1950082A (zh) * | 2004-03-03 | 2007-04-18 | 凯莫森特里克斯股份有限公司 | 双环和桥连的含氮杂环化物 |
| CN1976702A (zh) * | 2004-06-28 | 2007-06-06 | 因赛特公司 | 作为趋化因子受体调节剂的3－氨基环戊烷甲酰胺类 |
Non-Patent Citations (1)
| Title |
|---|
| 趋化因子受体CXCR4在人肝癌细胞中的表达及意义;李楠;《第二军医大学硕士学位论文》;20080228;第3-4，7-8，38-45页 * |
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US11639353B2 (en) | Cyclobutanes- and azetidine-containing mono and spirocyclic compounds as αV integrin inhibitors | |
| EP2976341B1 (en) | Acyclic cyanoethylpyrazolo pyridones as janus kinase inhibitors | |
| CN118894840A (zh) | Tlr7/8拮抗剂及其用途 | |
| TW202346289A (zh) | 作為ｇｌｐ—１ｒ促效劑的化合物 | |
| CN112513024A (zh) | Tlr7/8拮抗剂及其用途 | |
| US8946413B2 (en) | 3-aminocyclopentanecarboxamides as chemokine receptor agonists | |
| JP2023526840A (ja) | ピペラジン複素環アミド尿素類を含む受容体共役タンパク質１阻害剤 | |
| CN107207476A (zh) | 吲哚和氮杂吲哚衍生物及其用于神经退化性疾病中的用途 | |
| WO2022226182A1 (en) | Nek7 inhibitors | |
| JP2024512557A (ja) | Ｌｐａ受容体２阻害物質としての８－シクロ－置換キナゾリン誘導体 | |
| HK1161261B (en) | 3-aminocyclopentanecarboxamides as chemokine receptor modulators | |
| OA17116A (en) | Aminocyclopentanecarboxamides as chemokine receptor modulators | |
| HK40045245A (en) | Tlr7/8 antagonists and uses thereof | |
| HK1244786B (en) | Indole and azaindoles derivatives and their use in neurodegenerative diseases |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| REG | Reference to a national code |
Ref country code: HK Ref legal event code: DE Ref document number: 1161261 Country of ref document: HK |
|
| C14 | Grant of patent or utility model | ||
| GR01 | Patent grant | ||
| REG | Reference to a national code |
Ref country code: HK Ref legal event code: GR Ref document number: 1161261 Country of ref document: HK |
|
| CF01 | Termination of patent right due to non-payment of annual fee |
Granted publication date: 20140528 Termination date: 20201120 |
|
| CF01 | Termination of patent right due to non-payment of annual fee |